|
1
|
Hunter T: Protein kinases and
phosphatases: The yin and yang of protein phosphorylation and
signaling. Cell. 80:225–236. 1995. View Article : Google Scholar
|
|
2
|
Janssens V and Goris J: Protein
phosphatase 2A: A highly regulated family of serine/threonine
phosphatases implicated in cell growth and signalling. Biochem J.
353:417–439. 2001. View Article : Google Scholar
|
|
3
|
Lechward K, Awotunde OS, Swiatek W and
Muszyńska G: Protein phosphatase 2A: Variety of forms and diversity
of functions. Acta Biochim Pol. 48:921–933. 2001.
|
|
4
|
Virshup DM: Protein phosphatase 2A: A
panoply of enzymes. Curr Opin Cell Biol. 12:180–185. 2000.
View Article : Google Scholar
|
|
5
|
Sontag E: Protein phosphatase 2A: The
Trojan Horse of cellular signaling. Cell Signal. 13:7–16. 2001.
View Article : Google Scholar
|
|
6
|
Seshacharyulu P, Pandey P, Datta K and
Batra SK: Phosphatase: PP2A structural importance, regulation and
its aberrant expression in cancer. Cancer Lett. 335:9–18. 2013.
View Article : Google Scholar
|
|
7
|
Strack S, Chang D, Zaucha JA, Colbran RJ
and Wadzinski BE: Cloning and characterization of B delta, a novel
regulatory subunit of protein phosphatase 2A. FEBS Lett.
460:462–466. 1999. View Article : Google Scholar
|
|
8
|
Mayer RE, Hendrix P, Cron P, Matthies R,
Stone SR, Goris J, Merlevede W, Hofsteenge J and Hemmings BA:
Structure of the 55-kDa regulatory subunit of protein phosphatase
2A: Evidence for a neuronal-specific isoform. Biochemistry.
30:3589–3597. 1991. View Article : Google Scholar
|
|
9
|
Zolnierowicz S, Csortos C, Bondor J, Verin
A, Mumby MC and DePaoli-Roach AA: Diversity in the regulatory
B-subunits of protein phosphatase 2A: Identification of a novel
isoform highly expressed in brain. Biochemistry. 33:11858–11867.
1994. View Article : Google Scholar
|
|
10
|
Janssens V, Goris J and Van Hoof C: PP2A:
The expected tumor suppressor. Curr Opin Genet Dev. 15:34–41. 2005.
View Article : Google Scholar
|
|
11
|
Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y,
Xu Z and Han X: Cantharidin, a potent and selective PP2A inhibitor,
induces an oxidative stress-independent growth inhibition of
pancreatic cancer cells through G2/M cell-cycle arrest and
apoptosis. Cancer Sci. 101:1226–1233. 2010. View Article : Google Scholar
|
|
12
|
Schweyer S, Bachem A, Bremmer F,
Steinfelder HJ, Soruri A, Wagner W, Pottek T, Thelen P, Hopker WW,
Radzun HJ, et al: Expression and function of protein phosphatase
PP2A in malignant testicular germ cell tumours. J Pathol.
213:72–81. 2007. View Article : Google Scholar
|
|
13
|
Duong FH, Dill MT, Matter MS, Makowska Z,
Calabrese D, Dietsche T, Ketterer S, Terracciano L and Heim MH:
Protein phosphatase 2A promotes hepatocellular carcinogenesis in
the diethylnitrosamine mouse model through inhibition of p53.
Carcinogenesis. 35:114–122. 2014. View Article : Google Scholar
|
|
14
|
Lu J, Kovach JS, Johnson F, Chiang J,
Hodes R, Lonser R and Zhuang Z: Inhibition of serine/threonine
phosphatase PP2A enhances cancer chemotherapy by blocking DNA
damage induced defense mechanisms. Proc Natl Acad Sci USA.
106:11697–11702. 2009. View Article : Google Scholar
|
|
15
|
Boudreau RT, Conrad DM and Hoskin DW:
Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T
leukemia cells is negatively regulated by PP2A-associated p38
mitogen-activated protein kinase. Cell Signal. 19:139–151. 2007.
View Article : Google Scholar
|
|
16
|
Zhuang Q, Zhou T, He C, Zhang S, Qiu Y,
Luo B, Zhao R, Liu H, Lin Y and Lin Z: Protein phosphatase 2A-B55δ
enhances chemotherapy sensitivity of human hepatocellular carcinoma
under the regulation of microRNA-133b. J Exp Clin Cancer Res.
35:672016. View Article : Google Scholar
|
|
17
|
Cunningham CE, Li S, Vizeacoumar FS,
Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul
JM, McDonald M, et al: Therapeutic relevance of the protein
phosphatase 2A in cancer. Oncotarget. 7:61544–61561. 2016.
View Article : Google Scholar
|
|
18
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
19
|
Edge SB; American Joint Committee on
Cancer: AJCC Cancer Staging Manual. Springer; New York: 2010
|
|
20
|
Capes-Davis A, Theodosopoulos G, Atkin I,
Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA,
Reddel RR, et al: Check your cultures! A list of cross-contaminated
or misidentified cell lines. Int J Cancer. 127:1–8. 2010.
View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Rodgers JT, Vogel RO and Puigserver P:
Clk2 and B56β mediate insulin-regulated assembly of the PP2A
phosphatase holoenzyme complex on Akt. Mol Cell. 41:471–479. 2011.
View Article : Google Scholar
|
|
23
|
Zeng Q, Zhang H, Qin J, Xu Z, Gui L, Liu
B, Liu C, Xu C, Liu W, Zhang S, et al: Rapamycin inhibits
BAFF-stimulated cell proliferation and survival by suppressing
mTOR-mediated PP2A-Erk1/2 signaling pathway in normal and
neoplastic B-lymphoid cells. Cell Mol Life Sci. 72:4867–4884. 2015.
View Article : Google Scholar
|
|
24
|
Sablina AA, Hector M, Colpaert N and Hahn
WC: Identification of PP2A complexes and pathways involved in cell
transformation. Cancer Res. 70:10474–10484. 2010. View Article : Google Scholar
|
|
25
|
Kalev P, Simicek M, Vazquez I, Munck S,
Chen L, Soin T, Danda N, Chen W and Sablina A: Loss of PPP2R2A
inhibits homologous recombination DNA repair and predicts tumor
sensitivity to PARP inhibition. Cancer Res. 72:6414–6424. 2012.
View Article : Google Scholar
|
|
26
|
Zhou P, Shaffer DR, Alvarez Arias DA,
Nakazaki Y, Pos W, Torres AJ, Cremasco V, Dougan SK, Cowley GS,
Elpek K, et al: In vivo discovery of immunotherapy targets in the
tumour microenvironment. Nature. 506:52–57. 2014. View Article : Google Scholar
|
|
27
|
Eichhorn PJ, Creyghton MP and Bernards R:
Protein phosphatase 2A regulatory subunits and cancer. Biochim
Biophys Acta. 1795:1–15. 2009.
|
|
28
|
Letourneux C, Rocher G and Porteu F:
B56-containing PP2A dephosphorylate ERK and their activity is
controlled by the early gene IEX-1 and ERK. EMBO J. 25:727–738.
2006. View Article : Google Scholar
|
|
29
|
Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY
and Chiang CW: Regulation of phosphorylation of Thr-308 of Akt,
cell proliferation, and survival by the B55alpha regulatory subunit
targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol
Chem. 283:1882–1892. 2008. View Article : Google Scholar
|
|
30
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar
|
|
31
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar
|
|
32
|
Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X,
Barzegar M, Chung J and Huang S: Both mTORC1 and mTORC2 are
involved in the regulation of cell adhesion. Oncotarget.
6:7136–7150. 2015.
|
|
33
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar
|
|
34
|
Zhang Q and Claret FX: Phosphatases: The
new brakes for cancer development? Enzyme Res. 2012:6596492012.
View Article : Google Scholar
|
